Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Kyntra Bio's Enterprise Value for the quarter that ended in Mar. 2026 was $-25.64 Mil.
Kyntra Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio EV-to-EBIT Related Terms
Kyntra Bio EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Kyntra Bio's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IL8 vs ACTU, PLRZ, IGC: EV-to-EBIT Comparison
For the Biotechnology subindustry, Kyntra Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyntra Bio EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyntra Bio's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kyntra Bio's EV-to-EBIT falls into.
Kyntra Bio's current Enterprise Value is $113.29 Mil.
Kyntra Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio (LTS:0IL8) has a EV-to-EBIT of -2.37 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kyntra Bio and its competitors. According to the industry distribution chart, Kyntra Bio ranks #999999 out of 372 companies in the Biotechnology industry.
Is Kyntra Bio's EV-to-EBIT too high?
Kyntra Bio's current EV-to-EBIT is -2.37. Based on the distribution chart, Kyntra Bio ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kyntra Bio has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's EV-to-EBIT compare to ACTU and PLRZ?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #999999 out of 372 companies for EV-to-EBIT. This places Kyntra Bio in the lower half of its industry. The industry median EV-to-EBIT is 15.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.09, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kyntra Bio and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyntra Bio's current EV-to-EBIT is -2.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Fairly Valued. The stock's GF Value™ is $7.89, compared to a current price of $7.32 — trading 7.2% below its estimated fair value. The current EV-to-EBIT is -2.37. Kyntra Bio's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current EV-to-EBIT is -2.37 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?
Based on GuruFocus' analysis, Kyntra Bio stock appears to be undervalued.
The current stock price of $7.32 is trading 7.2% below its estimated GF Value™ of $7.89.
GuruFocus considers Kyntra Bio to be Fairly Valued.
Key valuation signals for LTS:0IL8:
EV-to-EBIT: -2.37
GF Value™: $7.89 vs. price of $7.32 (7.2% below fair value)
No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
63GF Score
Get the complete analysis for LTS:0IL8
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IL8 has been successfully added to your 
